Clinical Trials Directory

Trials / Sponsors / Cosmo Technologies Ltd

Cosmo Technologies Ltd

Industry · 12 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingStudy to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10
EARLY_Phase 12022-06-14
CompletedRifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
Diarrhea-predominant Irritable Bowel Syndrome
Phase 22017-12-18
CompletedSafety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to
Adenomas
N/A2016-02-01
CompletedPharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses i
Healthy
Phase 12015-07-01
CompletedThe Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Sc
Colorectal Cancer
Phase 32013-09-01
CompletedEffect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Colorectal Cancer
Phase 22013-02-01
CompletedPolyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Sub
Polyp and Adenoma Detection During Colonoscopy
—2012-01-01
CompletedNeoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Ulcerative Colitis
Phase 22012-01-01
CompletedColon Staining Efficacy of Single Oral Doses of Methylene Blue MMX
Colon Staining in Preparation for Colonoscopy
Phase 22011-05-02
CompletedStudy to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler'
Traveler's Diarrhea
Phase 32010-05-27
CompletedEfficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea
Infectious Diarrhoea
Phase 22008-02-01
CompletedEfficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administere
Ulcerative Colitis
Phase 22007-01-01